PMID- 30924296
OWN - NLM
STAT- MEDLINE
DCOM- 20200129
LR  - 20200129
IS  - 1756-185X (Electronic)
IS  - 1756-1841 (Linking)
VI  - 22
IP  - 6
DP  - 2019 Jun
TI  - Association of cardiac magnetic resonance-detected myocardial abnormalities with 
      disease characteristics and brain natriuretic peptide levels in systemic 
      sclerosis without cardiac symptoms.
PG  - 1016-1022
LID - 10.1111/1756-185X.13540 [doi]
AB  - AIM: This study aimed to evaluate the association between myocardial 
      abnormalities and left ventricular (LV) geometry as assessed using cardiac 
      magnetic resonance imaging (CMRI) in systemic sclerosis (SSc) patients without 
      cardiac symptoms. METHODS: SSc patients without cardiac symptoms or 
      cardiovascular risk factors underwent contrast CMRI. CMRI were assessed for 
      structural and functional LV parameters and myocardial fibrosis based on 
      myocardial late gadolinium enhancement (LGE). The correlation between brain 
      natriuretic peptide (BNP) levels and LGE status was evaluated. RESULTS: Among 49 
      patients, 27 (55%) showed LGE positivity. The most common identified LGE pattern 
      was a linear pattern. LGE was not consistent with coronary artery distribution. 
      There was no difference in ejection fraction between those with and without LGE. 
      LV morphological changes were observed in 29% of SSc patients. An abnormal LV 
      structure was detected in 44% and 14% of patients in the LGE+ and LGE- groups, 
      respectively. The BNP levels were higher by 57% in the LGE+ group than in the 
      LGE-group. Receiver operating characteristic analysis showed that BNP levels 
      reliably detected myocardial abnormalities (area under the curve, 0.72; 95% 
      confidence interval 0.58-0.88). CONCLUSIONS: Myocardial abnormalities were common 
      in SSc patients without cardiac symptoms. We suggest that LV morphological 
      changes may have resulted from myocardial abnormalities. BNP may be useful as a 
      screening tool for the detection of myocardial abnormalities in SSc patients.
CI  - (c) 2019 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons 
      Australia, Ltd.
FAU - Sugiyama, Kaita
AU  - Sugiyama K
AD  - Division of Hematology and Rheumatology, Nihon University School of Medicine, 
      Tokyo, Japan.
FAU - Kobayashi, Hitomi
AU  - Kobayashi H
AD  - Division of Hematology and Rheumatology, Nihon University School of Medicine, 
      Tokyo, Japan.
FAU - Kobayashi, Yasuyuki
AU  - Kobayashi Y
AD  - Department of Advanced Biomedical Imaging Informatics, St. Marianna University 
      School of Medicine, Kawasaki, Japan.
FAU - Yokoe, Isamu
AU  - Yokoe I
AD  - Division of Internal Medicine, Kyoundo Hospital, Tokyo, Japan.
FAU - Takei, Masami
AU  - Takei M
AD  - Division of Hematology and Rheumatology, Nihon University School of Medicine, 
      Tokyo, Japan.
FAU - Kitamura, Noboru
AU  - Kitamura N
AUID- ORCID: 0000-0002-7817-6941
AD  - Division of Hematology and Rheumatology, Nihon University School of Medicine, 
      Tokyo, Japan.
LA  - eng
PT  - Journal Article
DEP - 20190328
PL  - England
TA  - Int J Rheum Dis
JT  - International journal of rheumatic diseases
JID - 101474930
RN  - 0 (Biomarkers)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Asymptomatic Diseases
MH  - Biomarkers/blood
MH  - Female
MH  - Fibrosis
MH  - Humans
MH  - Hypertrophy, Left Ventricular/blood/*diagnostic 
      imaging/epidemiology/physiopathology
MH  - Japan/epidemiology
MH  - *Magnetic Resonance Imaging, Cine
MH  - Male
MH  - Middle Aged
MH  - Myocardium/pathology
MH  - Natriuretic Peptide, Brain/*blood
MH  - Predictive Value of Tests
MH  - Prevalence
MH  - Prognosis
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - Scleroderma, Systemic/diagnosis/*epidemiology
MH  - *Ventricular Function, Left
MH  - *Ventricular Remodeling
OTO - NOTNLM
OT  - brain natriuretic peptide
OT  - cardiac magnetic resonance imaging
OT  - late gadolinium enhancement
OT  - myocardial abnormalities
OT  - systemic sclerosis
EDAT- 2019/03/30 06:00
MHDA- 2020/01/30 06:00
CRDT- 2019/03/30 06:00
PHST- 2018/07/26 00:00 [received]
PHST- 2019/01/29 00:00 [revised]
PHST- 2019/02/13 00:00 [accepted]
PHST- 2019/03/30 06:00 [pubmed]
PHST- 2020/01/30 06:00 [medline]
PHST- 2019/03/30 06:00 [entrez]
AID - 10.1111/1756-185X.13540 [doi]
PST - ppublish
SO  - Int J Rheum Dis. 2019 Jun;22(6):1016-1022. doi: 10.1111/1756-185X.13540. Epub 
      2019 Mar 28.